Cargando…

Bayesian designs of phase II oncology trials to select maximum effective dose assuming monotonic dose-response relationship

BACKGROUND: For many molecularly targeted agents, the probability of response may be assumed to either increase or increase and then plateau in the tested dose range. Therefore, identifying the maximum effective dose, defined as the lowest dose that achieves a pre-specified target response and beyon...

Descripción completa

Detalles Bibliográficos
Autores principales:	Guo, Beibei, Li, Yisheng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4119476/ https://www.ncbi.nlm.nih.gov/pubmed/25074481 http://dx.doi.org/10.1186/1471-2288-14-95

Ejemplares similares

Bayesian dose-finding designs for combination of molecularly targeted agents assuming partial stochastic ordering
por: Guo, Beibei, et al.
Publicado: (2014)

Bayesian optimization for estimating the maximum tolerated dose in Phase I clinical trials
por: Takahashi, Ami, et al.
Publicado: (2021)

SCI: A Bayesian adaptive phase I/II dose‐finding design accounting for semi‐competing risks outcomes for immunotherapy trials
por: Zhang, Yifei, et al.
Publicado: (2022)

Extensions of the mTPI and TEQR designs to include non-monotone efficacy in addition to toxicity for optimal dose determination for early phase immunotherapy oncology trials
por: Ananthakrishnan, Revathi, et al.
Publicado: (2018)

Bayesian dose regimen assessment in early phase oncology incorporating pharmacokinetics and pharmacodynamics
por: Gerard, Emma, et al.
Publicado: (2021)

Non-monotonic dose-response relationships and endocrine disruptors: a qualitative method of assessment
por: Lagarde, Fabien, et al.
Publicado: (2015)

Dose-escalated Radiotherapy with Simultaneous Integrated Boost for Bone Metastases in Selected Patients with Assumed Favourable Prognosis
por: Potkrajcic, Vlatko, et al.
Publicado: (2022)

Assessing dose–response relationships for endocrine disrupting chemicals (EDCs): a focus on non-monotonicity
por: Zoeller, R Thomas, et al.
Publicado: (2015)

Dose Titration Algorithm Tuning (DTAT) should supersede ‘the’ Maximum Tolerated Dose (MTD) in oncology dose-finding trials
por: Norris, David C.
Publicado: (2017)

Adaptive designs for phase II cross-over dose-finding trials using Bayesian model averaging
por: Simpson, Sarah, et al.
Publicado: (2015)

Modulation of Cytochrome P450 2A5 Activity by Lipopolysaccharide: Low-Dose Effects and Non-Monotonic Dose-Response Relationship
por: De-Oliveira, Ana C. A. X., et al.
Publicado: (2015)

A software tool for both the maximum tolerated dose and the optimal biological dose finding trials in early phase designs
por: Li, Chen, et al.
Publicado: (2022)

Non-monotonous dose response function of the termination of spiral wave chaos
por: Lilienkamp, Thomas, et al.
Publicado: (2022)

Maximum Doses of Medicine
por: Kinglake,
Publicado: (1822)

Adaptive design for identifying maximum tolerated dose early to accelerate dose-finding trial
por: Kojima, Masahiro
Publicado: (2022)

An information theoretic phase I–II design for molecularly targeted agents that does not require an assumption of monotonicity
por: Mozgunov, Pavel, et al.
Publicado: (2018)

Bayesian modeling of a bivariate toxicity outcome for early phase oncology trials evaluating dose regimens
por: Gerard, Emma, et al.
Publicado: (2021)

Evaluation of a multi-arm multi-stage Bayesian design for phase II drug selection trials – an example in hemato-oncology
por: Jacob, Louis, et al.
Publicado: (2016)

The Effect of Low Monotonic Doses of Zearalenone on Selected Reproductive Tissues in Pre-Pubertal Female Dogs—A Review
por: Gajęcka, Magdalena, et al.
Publicado: (2015)

Subgroup‐specific dose finding for phase I‐II trials using Bayesian clustering
por: Curtis, Alexandra, et al.
Publicado: (2022)

Monotone and near-monotone biochemical networks
por: Sontag, Eduardo D.
Publicado: (2007)

Maximum Tolerated Dose Evaluation of the AMPA Modulator Org 26576 in Healthy Volunteers and Depressed Patients: A Summary and Method Analysis of Bridging Research in Support of Phase II Dose Selection
por: Nations, Kari R., et al.
Publicado: (2012)

Evaluation of the relationship between phantom position and computed tomography dose index in cone beam computed tomography when assuming breast irradiation
por: Ueno, Hiroyuki, et al.
Publicado: (2021)

Opinion on the impact of non‐monotonic dose responses on EFSA′s human health risk assessments
por: More, Simon, et al.
Publicado: (2021)

Reinforcement learning and Bayesian data assimilation for model‐informed precision dosing in oncology
por: Maier, Corinna, et al.
Publicado: (2021)

A dose-finding design for phase I clinical trials based on Bayesian stochastic approximation
por: Xu, Jin, et al.
Publicado: (2022)

Experimental designs for phase I and phase I/II dose-finding studies
por: O'quigley, J, et al.
Publicado: (2006)

Practical considerations for the implementation of adaptive designs for oncology Phase I dose-finding trials
por: Wei, Lai, et al.
Publicado: (2019)

Designing phase I oncology dose escalation using dose–exposure–toxicity models as a complementary approach to model‐based dose–toxicity models
por: Pantoja, Kristyn, et al.
Publicado: (2022)

Impact of race on dose selection of molecular-targeted agents in early-phase oncology trials
por: Yokota, Tomoya, et al.
Publicado: (2018)

Bayesian dose selection design for a binary outcome using restricted response adaptive randomization
por: Meinzer, Caitlyn, et al.
Publicado: (2017)

Assume, Guarantee or Repair
por: Frenkel, Hadar, et al.
Publicado: (2020)

Safety and efficacy of the maximum tolerated dose of givinostat in polycythemia vera: a two-part Phase Ib/II study
por: Rambaldi, Alessandro, et al.
Publicado: (2020)

Minimax and monotonicity
por: Simons, Stephen
Publicado: (1998)

Monotonous Diet
Publicado: (1890)

On (Non-)Monotonicity and Phase Diagram of Finitary Random Interlacement
por: Cai, Zhenhao, et al.
Publicado: (2021)

A Bayesian dose-finding procedure applied to a seamless phase I/II trial in rheumatoid arthritis
por: Whitehead, Anne, et al.
Publicado: (2011)

Ordered, Random, Monotonic and Non-Monotonic Digital Nanodot Gradients
por: Ongo, Grant, et al.
Publicado: (2014)

A Novel Bayesian Seamless Phase I/II Design
por: Pan, Haitao, et al.
Publicado: (2013)

A Bayesian Adaptive Design in Cancer Phase I Trials Using Dose Combinations with Ordinal Toxicity Grades
por: Diniz, Márcio A, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_32heq0fibrbq3tt35qe5m41s6v